Department of Medicine, Christchurch Kidney Research Group, University of Otago, Christchurch, New Zealand.
Nephrol Dial Transplant. 2010 Jan;25(1):107-18. doi: 10.1093/ndt/gfp501. Epub 2009 Oct 7.
The risk, injury, failure, loss-of-function, end-stage-renal-failure (RIFLE) and acute kidney injury network (AKIN) consensus definitions of acute kidney injury (AKI) were established in part to facilitate comparison of trials. Contrast-induced nephropathy (CIN) has traditionally used a less demanding definition.
To review use of RIFLE and AKIN as AKI trial outcome variables and contrast these with outcomes for CIN.
We conducted a search of PubMed from 1 January 2005 to 31 December 2008 and 9 trial registries for randomized control trials for preventional or interventional treatment of AKI and CIN.
RIFLE or AKIN were outcome variables in 36% (n = 8) of the published (n = 22) and 18% (n = 4) of the current (n = 22) AKI trials. RIFLE was used to triage to intervention in three trials. The urine output definition of RIFLE and AKIN was an outcome in only two trials. In 18% (n = 8) of AKI trials, the CIN definition (increase in serum creatinine of > or =25% and/or > or =44 micromol/l) was the primary outcome. This was also the primary outcome in 56% (n = 13) of published (n = 12) and current (n = 11) CIN trials. Three published CIN trials used RIFLE or AKIN as an outcome (13%). The duration over which outcomes were determined varied from 24 h to 7 days.
Considerable heterogeneity remains in outcome variables of AKI and CIN clinical trials. Even when the RIFLE or AKIN criteria were used, they were not applied consistently. There is a need for further consensus on surrogate outcome variables.
风险、损伤、衰竭、失能、终末期肾脏衰竭(RIFLE)和急性肾损伤网络(AKIN)急性肾损伤(AKI)共识定义部分是为了便于试验比较而建立的。传统上,对比剂肾病(CIN)使用的是要求较低的定义。
回顾 RIFLE 和 AKIN 作为 AKI 试验结局变量的应用,并将其与 CIN 的结局进行比较。
我们在 PubMed 上进行了一次检索,检索时间为 2005 年 1 月 1 日至 2008 年 12 月 31 日,还检索了 9 个试验注册处,寻找预防或干预治疗 AKI 和 CIN 的随机对照试验。
36%(n = 8)已发表(n = 22)和 18%(n = 4)当前(n = 22)AKI 试验(n = 22)将 RIFLE 或 AKIN 作为结局变量。有 3 项试验使用 RIFLE 进行分诊干预。只有两项试验将 RIFLE 和 AKIN 的尿量定义作为结局。在 18%(n = 8)的 AKI 试验中,CIN 定义(血清肌酐增加≥25%和/或≥44 μmol/L)是主要结局。这也是 56%(n = 13)已发表(n = 12)和当前(n = 11)CIN 试验(n = 13)的主要结局。有 3 项已发表的 CIN 试验将 RIFLE 或 AKIN 作为结局(13%)。确定结局的时间从 24 小时到 7 天不等。
AKI 和 CIN 临床试验的结局变量仍存在很大的异质性。即使使用了 RIFLE 或 AKIN 标准,也没有一致地应用。需要进一步就替代结局变量达成共识。